Probability of Anti PDGF/R as Antiangiogenic Nasopharyngeal Carcinoma: A Review by Oke Kadarullah
International Journal of Nasopharyngeal Carcinoma (IJNPC) Vol. 02, No. 04, December 2020 | 101-102 
 




Journal homepage: https://talenta.usu.ac.id/IJNPC 
 
 





Probability of Anti PDGF/R as Antiangiogenic Nasopharyngeal Carcinoma:               
A Review 
Oke Kadarullah* 
Departement of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Muhammadiyah Purwokerto-PKU Muhammadiyah Gombong 
Hospital, Indonesia 
Abstract  Article Info 
Introduction: Nasopharyngeal Carcinoma (NPC) is frequently found in Southeast Asia, especially in Indonesia, 
with a higher incidence rate compared to global numbers. The mortality rate of NPC in Indonesia is also higher 
than the standardized mortality rate. Radiotherapy and chemotherapy are the first line treatment, but still has 5-
10% chance of recurrence. NPC is mostly persistence and recurrence, and this itself is a challenge in achieving 
effective treatment. Patients in Indonesia commonly search for treatment at an advanced stage. 
Discussion: Advanced stage NPC requires an additional combination therapy such as chemotherapy and 
targeted therapy. Targeted therapy in the past 10 years have not shown a significant improvement in recurrent 
NPC. Cetuximab is the empiric choice for head and neck squamous cell carcinoma. EGFR and VEGFR are 
target molecules tyrosine kinase, including PDGF/R, which plays a role in angiogenesis and cancer 
progressivity. PDGF and its receptors shows an important role in certain cancers including head and neck cancer.  
PDGF/R in NPC has been researched in vitro and in vivo but more clinical data is still needed.  
Conclusion: The role of PDGF/PDGFR in targeted therapy development is still being used. This is to push the 
anti-angiogenic combination strategy as an option for NPC with radio-chemotherapy resistance, or for stable, 
progressive and recurrent NPC while considering its unwanted effects. 
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1. INTRODUCTION 
Nasopharyngeal cancer (NPC) is frequently found in Southeast Asia, with 
the most commonly found histologically is undifferentiated carcinoma. 
Indonesia is the Southeast Asian country with the highest NPC incidence, 
followed by Vietnam and Malaysia, and is even higher than India (South Asia) 
[1,2]. The data in Indonesia is considered not clear and this is caused by 
uncomprehensive cancer registration. However, relatively, the incidence in 
Indonesia is around 5.7 per 100,000 in men, and 1.9 per 100,000 in women. 
Globally, the incidence of NPC in men is only 1.9 per 100.000 and 0.8 per 
100,000 in women [3]. In 2012, mortality caused by NPC reached 50,831 
(35,756 men, and 15,075 women). While the world standardized mortality rate 
is 0.7 per 100,000 (1.0 per 100,000 in men, and 0.4 per 100,000 in women) [4]. 
This malignancy is sensitive towards radiotherapy and chemotherapy; hence 
they remain the first line treatment. However, even after sophisticated radiation 
techniques, as well as a number of chemotherapy schemes, there are 5% - 10% 
patients who still experience recurrence. NPC is a persistent and recurrent 
disease, and this is a challenge for all health workers to achieve an effective 
treatment [1]. Patients in Indonesia commonly start searching for treatments at 
an advanced stage and already with metastases [5]. 
2. MAIN TEXT 
2.1 Therapy controversy 
Patients with advanced stage NPC requires additional combination 
of systemic therapy such as chemotherapy and targeted therapy. 
Targeted therapy has emerged since the past 10 years as another option 
for NPC. However, only few clinical trials show a significant 
improvement in recurrent NPC. Referring to head and neck squamous 
cell carcinoma empirical therapy, cetuximab (EGFR inhibitor), as of 
now is the most common targeted therapy used [6]. But targeted therapy 
hasn’t shown a significant effect towards NPC. Epidermal growth factor 
receptor (EGFR) inhibitors shows minimal activity, and vascular 
endothelial growth factor (VEGF) targeted therapy shows limited 
activity with risk of bleeding [7].  
EGFR and VEGFR are target molecules in tyrosine kinases group, which 
also consist of HER2, ALK, ROS1, MET, insulin-like growth factor 1 receptor 
(IGF1R), fibroblast growth factor receptor (FGFR) as well as PDGFR, where it 
is a focus in therapy development for cancer patients [8].  
 
2.2 PDGFR in angiogenesis 
PDGFR (platelet-derived growth factor receptor) family, also 
known as RTK class III consists of PDGFRα, PDGFRβ, KIT (CD117, 
stem cell factor receptor), colony-stimulating factor 1 receptor and 
Fms-like tyrosine kinase 3 [9]. 
Like VEGFR, PDGF/PDGFR also plays a role in tumor 
angiogenesis pathway as well as an alternative inducer in tumor growth. 
Cancer invades and metastases and this is facilitated by angiogenesis as 
a control point in cancer progressivity. However, this process is not yet 
completely understood because it involves many cellular signaling 
pathways. Platelet-derived growth factor (PDGF) and PDGF receptor 
(PDGFR) signaling pathway, for example, may provide a potential 
escape mechanism for anti-VEGF/VEGFR therapy which can facilitate 
the start of tumor growth resulting in tumor resistance. So, anti-
angiogenic strategy for cancer, including PDGF/PDGFR may be 
considered as a new therapy in advanced stage solid tumor [10]. 
2.3 PDGF/R in malignancy 
PDGF and its receptor plays an important role in a number of 
cancers, such as lung, prostate, kidney cancer, leukemia (CMML) and 
glioblastoma. PDGF signals in those malignancies have a role in tumor 
progression, such as stimulating cancer autocrine as well as paracrine 
interaction involving surrounding stroma and vascular.[11] In oral 
squamous cell carcinoma, an overexpression of PDGF/PDGFR is found, 
and it is related to tumor genesis and a bad prognosis  [12]. 
Targeted PDGFR therapy has been developed for several malignancies 
including neurofibromatosis, leukemia (CML, ALL) prostate cancer, 
NHML, dermatofibrosarcoma, melanoma malignancy, breast cancer, cell B 
lymphoma, gall bladder, colorectal, renal, non-small cell lung, pancreatic, 
thyroid, esophageal and head-neck cancer [13]. 







2.4 PDGF/R in nasopharyngeal cancer 
Likewise, in NPC, a number of molecular pathways can mediate 
angiogenesis process, cell growth, apoptosis, migration and invasion. 
Hence, an understanding of these molecular pathways may be a new strategy 
for NPC diagnoses, prognosis and treatment. One of them is a disturbance 
in receptor tyrosine kinase (RTK) expression regulation. An overexpression 
of EGF receptors and VEGF receptors are often found in NPC. However, 
the expression of PDGF and FGF receptors have not been researched in 
clinical NPC [14]. As far as literature search, not many researches in PDGF 
and PDGFR in nasopharyngeal cancer has been done. 
Sunitinib is a multiple tyrosine kinase inhibitor, among them it inhibits 
PDGFR which is researched for a number of solid tumor and acute 
leukemia. In these researches, a drug trial for NPC cells and NPC xenograft 
was conducted, and showed that sunitinib effectively inhibits NPC cells 
(invitro) and suppresses tumor growth in experimental animals (inivo) [15].  
Famitinib is a new tyrosine kinase inhibitor which significantly increases 
the radiosensitivity of NPC cells (CNE2) through in vitro and in vivo trials 
by enhancing inducted radiation of PDGFR, phosphorylation c-kit as well 
as impeding micro vascular formation [16]. A recommended dose for 
Famitinib phase 2 clinical trial was achieved, which is 20 mg combined with 
radiotherapy for advanced stage NPC, and which further investigation on 
combined chemoradiation therapy for advanced locoregional NPC was 
recommended [17]. 
3. CONCLUSION 
Angiogenesis in nasopharyngeal cancer plays a major role in the 
progression to NPC metastases. A number of signaling proteins are important 
in this process, including VEGF and its receptors, which have been used in 
clinical empirically. However, it is suspected that the angiogenesis signal at 
NPC is not only single, but it is suspected that it is mediated by PDGF and its 
receptors and other proteins. Perhaps this complex condition underlies the 
failure of current NPC therapy. 
The role of PDGF/PDGFR in targeted therapy development is still being 
used. This is to push the anti angiogenic combination strategy as an option for 
NPC with chemotherapy resistance, or as targeted therapy for stable, 
progressive and recurrent NPC while considering its unwanted effects. 
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